Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 3/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.36 |
| ▸ | BCR | P11274 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15171999 | 0.91 | ACHE (0.36) | PDE4APDE4BPDE4CPDE4DCA4 | |
| SCHEMBL15172001 | 0.91 | ACHE (0.36) | PDE4APDE4BPDE4CPDE4DCA4 | |
| SCHEMBL1817023 | 0.89 | ALDH1A1 (0.46) | PDE4APDE4BPDE4CPDE4DSMN1; SMN2 | |
| SCHEMBL8131087 | 0.89 | KIF11 (0.44) | CA4SMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL1011203 | 0.86 | KIF11 (0.45) | CA4SMN1; SMN2HTTLMNAKIF11 | |
| SCHEMBL15154726 | 0.83 | KDM4E (0.35) | SMN1; SMN2LMNAALDH1A1ABCB1CYP3A4 | |
| SCHEMBL23919140 | 0.82 | LTA4H (0.53) | CA4SMN1; SMN2HTTLMNAALDH1A1 | |
| Dimethylamine SCHEMBL6491084 | 0.82 | LMNA (0.43) | CA4SMN1; SMN2NPC1HTTRAB9A | |
| SCHEMBL11914194 | 0.81 | ALDH1A1 (0.38) | PDE4APDE4BPDE4CPDE4DSMN1; SMN2 | |
| SCHEMBL11573349 | 0.81 | TUBB4A (0.42) | PDE4DSMN1; SMN2HTTALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012156591-A1 | RUTHNIUM-BASED CATALYTIC COMPOSITION INCLUDING A SILANE OR SILOXANE COMPOUND AND METHOD FOR METHASIZING OLEFINS USING SAID COMPOSITION | IFP Energies Nouvelles (FR) | 2012-11-22 | — | — | WO | claimed |
| US-20170022232-A1 | METHOD FOR IN-SITU FORMATION OF METATHESIS CATALYSTS | SCHRODI YANN (US) | 2017-01-26 | — | — | US | disclosed |
| US-20170022232-A1 | METHOD FOR IN-SITU FORMATION OF METATHESIS CATALYSTS | SCHRODI YANN (US) | 2017-01-26 | — | — | US | disclosed |
| US-9273081-B2 | Method for in-situ formation of metathesis catalysts | ExxonMobil Product Solutions Company | 2016-03-01 | — | — | US | disclosed |
| US-9273081-B2 | Method for in-situ formation of metathesis catalysts | ExxonMobil Product Solutions Company | 2016-03-01 | — | — | US | disclosed |
| US-20150299235-A1 | METHOD FOR IN-SITU FORMATION OF METATHESIS CATALYSTS | ExxonMobil Product Solutions Company | 2015-10-22 | — | — | US | disclosed |
| US-20150299235-A1 | METHOD FOR IN-SITU FORMATION OF METATHESIS CATALYSTS | ExxonMobil Product Solutions Company | 2015-10-22 | — | — | US | disclosed |
| US-20130204026-A1 | METHOD FOR IN-SITU FORMATION OF METATHESIS CATALYSTS | MATERIA, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130204026-A1 | METHOD FOR IN-SITU FORMATION OF METATHESIS CATALYSTS | MATERIA, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| WO-2012156591-A1 | RUTHNIUM-BASED CATALYTIC COMPOSITION INCLUDING A SILANE OR SILOXANE COMPOUND AND METHOD FOR METHASIZING OLEFINS USING SAID COMPOSITION | IFP Energies Nouvelles (FR) | 2012-11-22 | — | — | WO | disclosed |
| WO-2011119778-A2 | METHOD FOR IN-SITU FORMATION OF METATHESIS CATALYSTS | SCHRODI YANN (US) | 2011-09-29 | — | — | WO | disclosed |
| WO-2011119778-A2 | METHOD FOR IN-SITU FORMATION OF METATHESIS CATALYSTS | SCHRODI YANN (US) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299235-A1 | METHOD FOR IN-SITU FORMATION OF METATHESIS CATALYSTS | CHRM1, ACSL1, LOXL1 | PDE4A 4879/4885PDE4B 4880/4885PDE4C 4855/4885 |
| US-20170022232-A1 | METHOD FOR IN-SITU FORMATION OF METATHESIS CATALYSTS | CHRM1, ACSL1, LOXL1 | PDE4A 4879/4885PDE4B 4880/4885PDE4C 4855/4885 |
| US-20130204026-A1 | METHOD FOR IN-SITU FORMATION OF METATHESIS CATALYSTS | CHRM1, ACSL1, LOXL1 | PDE4A 4879/4885PDE4B 4880/4885PDE4C 4855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.